▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Iambic Therapeutics Named to the Endpoints 11 List of Biotech’s Most Promising Startups

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced its inclusion in the 2024 Endpoints News list o...

Business Wire

SAN DIEGO: Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced its inclusion in the 2024 Endpoints News list of “Biotech’s Most Promising Startups.” The annual Endpoints 11 award recognizes emerging life science companies pushing the frontiers of innovation to create breakthrough therapies for patients.

“Integrating AI and machine learning with automated experimentation has helped Iambic redefine the pace and precision of drug discovery. Our platform has enabled us to advance our lead program from discovery to the clinic in under 24 months – a transformative shift in traditional timelines,” said Tom Miller, PhD, Iambic’s CEO and co-founder. “This acknowledgment by Endpoints underscores our team’s relentless dedication to advancing novel, potential best-in-class and first-in-class treatments that address critical unmet needs in oncology and beyond.”

Iambic is developing an internal pipeline of candidates, discovered using its platform that integrates AI models for protein structure prediction and wholistic drug design with high-throughput chemistry and biology experimentation. Iambic’s pipeline currently includes IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs.

In a strategic research partnership announced this week with Lundbeck, Iambic will use its drug discovery platform to accelerate research into neurological disease – further expanding its potential impact in additional therapeutic areas.

About the Iambic Therapeutics Physics-Informed AI-Driven Discovery Platform

The Iambic Therapeutics AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Iambic NeuralPLexer, which provides state-of-the-art structural predictions of protein-ligand complexes. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform’s algorithms enable identification of new chemical mechanisms for engaging difficult-to-address biological targets, discovery of product profiles that optimize therapeutic window, and exploration of the chemical space to discover candidates for development with highly differentiated properties. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.

About Iambic Therapeutics

Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Dronus gets a strategic investment by Eni Next

Eni's VC company invest in the Italian drone company to develop new solutions for industrial plants monitoring

Technology Reply wins the 2024 Oracle Partner Awards - Europe South Innovation

Oracle recognizes Technology Reply’s ability to develop and deliver pioneering solutions through partnering with Oracle

25 Italian Startups Will Be Present at Expand North Star 2024

Scheduled for October, the world's largest startup event will bring together more than 2,000 exhibitors in Dubai, UAE

Most read

Contact Center Decisions Increasingly Focus on Customer Experience, New…

#BuyersGuide--Many enterprises are bypassing traditional call handling in favor of sophisticated contact center applications that meet customers in the…

Insta360 X4: Revolutionizing Reality Capture with Top Industry Integrations

#360camera--Insta360 announces the seamless integration of its flagship X4 camera with leading reality capture platforms, setting new standards for efficiency…

HPE Positioned as a Leader for Seven Years Running in 2024 Gartner® Magic…

Hewlett Packard Enterprise (NYSE: HPE) today announced Gartner has recognized HPE as a Leader in the 2024 Gartner Magic Quadrant for SD-WAN. This is the…

Nearly Half of Brits (46%) Admit to Shopping on Their Phone While at Work,…

Nearly half (46%) of Brits admit to shopping on their phone while at work, according to a new survey conducted by Attentive, an AI-powered SMS and email…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!